Highlights:
- Bacteriophages are potent therapeutics against biohazardous bacteria, which rapidly develop multidrug resistance.
- Routine administration of phage therapy is hampered by a lack of rapid production, safe bioengineering, and detailed characterization of phages.
- A cell-free platform has been developed for a broad spectrum of phages and which produced effective doses against enteroaggregative Escherichia coli (EAEC), Yersinia pestis, and Klebsiella pneumoniae.
- The range of cell-free production could be extended to phages targeting gram-positive bacteria.